300239 东宝生物
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)3.0617.5247.4163.0241.864
总资产报酬率 ROA (%)1.8454.7484.9522.0671.350
投入资产回报率 ROIC (%)2.2505.9376.4982.7081.654

边际利润分析
销售毛利率 (%)22.66125.53224.74415.71015.542
营业利润率 (%)14.50414.76413.8356.8114.402
息税前利润/营业总收入 (%)13.71914.69914.1877.1165.607
净利润/营业总收入 (%)12.47913.07012.2365.8524.054

收益指标分析
经营活动净收益/利润总额(%)94.69197.06894.05076.27867.535
价值变动净收益/利润总额(%)-3.480-2.996-1.451-6.084-7.109
营业外收支净额/利润总额(%)-1.2150.4250.860-0.368-0.468

偿债能力分析
流动比率 (X)4.4364.4853.2382.1181.380
速动比率 (X)3.3833.5492.2331.2970.561
资产负债率 (%)31.43630.95623.92724.0780.296
带息债务/全部投入资本 (%)23.16222.02710.5563.5656.788
股东权益/带息债务 (%)314.701336.709803.1612,548.9341,292.166
股东权益/负债合计 (%)191.054195.338276.775279.738235.844
利息保障倍数 (X)-22.454-114.32160.96421.5404.575

营运能力分析
应收账款周转天数 (天)66.01056.91756.58572.31779.367
存货周转天数 (天)163.765148.666168.312220.673246.056